We previously reported the effectiveness of trans-aconitic acid (TAA) as an antileishmanial compound.
used along with TAA (5 mM), the parasite loads were reduced by 100, 100, and 88.1%, respectively. TAA (5 mM) alone suppressed the amastigote burden by 59.5%. In experimental visceral leishmaniasis in hamsters (1-month model) , TAA at a dose of 200 mg/kg of body weight per day suppressed the spleen parasite load by 73.5%, and TAA in combination with sodium stibogluconate (50 mg of Sb per kg per day), pentamidine (8 mg/kg/day), and allopurinol (15 mg/kg/day) inhibited the spleen parasite load by 98, 98.9, and 97%, respectively. Individually, these three drugs inhibited the parasite load by 35, 20 , and 22%, respectively. TAA (400 mg/kg/day) inhibited the spleen parasite load by 99.8%, but an inhibitory effect of -100% was noted when TAA was supplemented with an antileishmanial drug. TAA was administered in experimental animals through oral, intraperitoneal, and intramuscular routes; the intramuscular route was most effective.
A parasitic protozoan, Leishmania donovani, is the causative agent of visceral leishmaniasis or kala-azar. Kala-azar patients are generally treated with sodium stibogluconate, pentamidine, allopurinol, etc. The modes of action of these drugs are different (3, 10, 20) . Other antileishmanial compounds are currently being tested (2, 21, 28, 30) . Sodium stibogluconate, pentamidine, and allopurinol are known to have toxic effects (7, 16, 17) . The number of drug-resistant and/or nonresponsive cases (2, 16 ) is gradually increasing, and new therapeutic regimens are needed.
Metabolic studies of leishmania have shown that fatty acids serve as an important energy source for the amastigotes, which oxidize fatty acids at about 10 times the rate by promastigotes (12) . Therefore, oxidation of the short-chain fatty acids via the Krebs cycle enzymes plays an important role in the energy metabolism of the amastigotes (13) . The importance of fatty acid oxidation and the inherent differences in energy metabolism between the parasite and host (24, 27, 33) prompted us to test the efficacy of trans-aconitic acid (TAA) as an antileishmanial agent with no known mammalian toxicity (25, 26) . It has been noted previously that TAA, an inhibitor of the enzyme aconitase, inhibits the growth of L. donovani, the etiological agent of kala-azar (26) .
In view of the toxic effects of the commonly used antileishmanial drugs and increase in the number of nonresponsive cases, combined chemotherapy has been introduced in the treatment of kala-azar; combined chemotherapy is the * Corresponding author.
use of sodium stibogluconate having more toxic effects in combination with a less toxic compound, allopurinol (8) . The present report deals with the efficacy of TAA in combined chemotherapy with either sodium stibogluconate, pentamidine, or allopurinol in animal models of visceral leishmaniasis.
MATERIALS AND METHODS
Parasite culture. L. donovani, strain MHOM/IN/86/LG, was used throughout the experiments and was obtained by culture of bone marrow of a patient in Nil Ratan Sircar Medical College, Calcutta, India (19) . The strain was maintained in hamsters (Mesocricetus auratus, obtained from Haffkine Research Institute and bred in our animal house). The promastigote form of the strain was obtained by transformation of the spleen amastigotes and cultured in supplemented RPMI 1640 (SR) medium. SR medium was RPMI 1640 medium (GIBCO) supplemented with HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer (GIBCO), L-glutamine (GIBCO), and 10% (vol/vol) heatinactivated fetal calf serum (GIBCO).
Preparation of macrophage monolayer. Macrophages prestimulated with 4% thioglycolate (26) were isolated from BALB/c mice (originally obtained from Charles River and then bred in our animal house) in SR medium by peritoneal lavage, and monolayers were prepared and incubated at 37°C for further growth as described previously (26) . These monolayers were used for experimentation.
In vitro multiplication of L. donovani promastigotes.
Freshly transformed promastigotes were centrifuged and washed twice in S-a-MEM (19) . traperitoneally for 5 consecutive days at doses up to 100 mg of Sb per kg per day. This treatment was then repeated after 10 days. Allopurinol (15 mg/kg/day) was administered orally for 15 consecutive days. Pentamidine was injected intraperitoneally for 10 alternate days at doses of 8 mg/kg/day. Animals were sacrificed on the 30th day of infection. Liver and spleen weights were noted, impression smears of the spleen were prepared, fixed, and Giemsa stained, and the total parasite burden in the spleen was determined microscopically (26, 34) . Similar control experiments were done with infected and uninfected animals with no drug treatment. For further confirmation, in vitro transformation was studied at 24°C with spleen pieces taken from animals in all experimental groups. Aliquots were withdrawn at intervals, and the presence of promastigotes was noted microscopically.
Statistical methods. The data were initially subjected to simple analysis of variance techniques. Two-way analysis of variance was done for the data in Table 2 in two experimental designs; in the 2 x 3 design, there were two levels of TAA dose and three levels of administration route and no control (no dose), whereas in the 3 x 3 design, the control (no-dose) level was the third level of TAA administered through the three different routes. The effect of dose is found highly significant (at 0.05% level) for both experimental designs. The effect of administration route is found to be significant at the 2.5% level but insignificant at the 1% level in the 2 x 3 design, whereas it is found to be insignificant at the 2.5% level in the 3 x 3 design. The interaction effect is absent at the 10% level of significance in both 2 x 3 and 3 x 3 designs. Dunnett's test for multiple comparison (36) was used to compare all the treated groups with a single control (no-drug) group (Tables 1 to 4 ). Tukey's test for multiple comparison (37) was performed for comparisons between the treated groups as indicated in Tables 1, 3 , and 4.
RESULTS
In vitro growth inhibition of L. donovani promastigotes by TAA. Multiplication of L. donovani promastigotes in vitro was inhibited by TAA in a dose-dependent manner, which was reversed by the addition of an equimolar amount of cis-aconitic acid (CAA) (Sigma) or citrate (Sigma). In the controls, where either CAA or citrate was added, enhanced multiplication of the parasite was observed (Fig. 1) .
Role of TAA in combination with other antileishmanial compounds on in vitro transformation of L. donovani amastigotes to promastigotes. TAA inhibited transformation of L. donovani amastigotes significantly (95.2%) at a dose of 2 mM. TAA at a dose of 10 mM completely inhibited the process. Slight positivity in transformation was observed after 96 h of incubation by TAA at 5 mM. Sodium stibogluconate (50 ,g of Sb per ml) did not inhibit transformation, but in combination with 5 mM TAA, it completely inhibited the process. Pentamidine (5 ,ug/ml) and allopurinol (10 ,ug/ ml) inhibited of transformation of amastigotes by 79 and 82%, respectively, at 120 h. Complete inhibition was brought about by these two compounds in combination with 5 mM TAA.
Inhibition of multiplication ofL. donovani within peritoneal macrophages in vitro. TAA at a dose of 5 mM reduced the number of amastigotes per infected macrophage by about 60%, but in combination with sodium stibogluconate at a dose of 20 ,ug of Sb per ml, it completely inhibited the process. Allopurinol at a dose of 5 ,ug/ml reduced the number of amastigotes by about 46%, but in combination with TAA (5 mM), it reduced the number of amastigotes by 88%. (14) , and 100% in Kenya erally of the T wave flattening or inverting (7) . It was further (22) . A subsequent course of treatment after an interval of 10 (15) . Although allopurinol inhibits the growth of Leishmania promatigotes in vitro, the inhibitory effect of the drug has been reported to be insufficient to resist growth of the parasites in visceral leishmaniasis cases (23) and particularly in previously untreated patients (18) , possibly because the amastigotes are exposed to high concentrations of host cell ATP and GTP (20) , which are utilized by the parasite after cleavage to their corresponding ribonucleosides (1, 4) . In spite of the theoretical activity of allopurinol against the purine scavenger pathway of Leishmania spp., it has been reported not to be so effective in cutaneous leishmaniasis caused by Leishmania panamensis, Leishmania guanensis, and Leishmania mexicana (11) . The adverse reaction associated with allopurinol is skin rash (17) . 37, 1993 Although a high dose of TAA is required for significant suppression of the parasite burden, TAA can be administered orally effectively and used successfully with low doses of other antileishmanial compounds without any apparent toxicity in the experimental animals even when it (400 mg/kg of body weight) was given for a longer period (Tables 2 and  4 ). Our previous study also showed that the mice did not die when TAA (2 g/kg of body weight) was administered intraperitoneally (26) .
The exact mechanism of action of TAA on the host and parasite is not known. Growth inhibition of Leishmania promastigotes suggests that energy metabolism of the parasite is highly susceptible to TAA. It is also evident from the strong inhibition of transformation that the biogenesis of mitochondria is also related to energy metabolism of the parasite. However, the inhibitory effect of TAA was greater in amastigotes than in promastigotes. The in vitro transformation of Trypanosoma brucei bloodstream forms to procyclic forms is reported to be stimulated by citrate or cisaconitate, which suggests the involvement of the Krebs cycle in morphogenesis of T. brucei (6) . The amastigote form of Leishmania spp. depends mostly on fatty acid oxidation via the Krebs cycle for its energy supply (12) .
The enzyme activities of the Krebs cycle for the host and the parasite are different. Citrate synthase is present in extremely low levels in Leishmania spp. (24, 27) , which limits the production of citrate. Reversal of the inhibitory action of TAA on aconitase of the parasite may be drastically hampered because of citrate limitation. On the other hand, a high level of citrate synthase is present in host cell mitochondria and may increase the supply of citrate that can reverse the inhibitory effect of TAA. There might be a difference in the mechanism of inhibition of the enzyme aconitase in the parasite and host. Isocitrate is formed from citrate by the action of aconitase, and it can also reverse the inhibitory action of TAA on aconitase. Isocitrate-mediated reversal of the inhibitory effect seems to be limited in the parasite because of retarded formation of isocitrate. Briefly, because of the limited supply of citrate and isocitrate, the reversal of aconitase inhibition by TAA may be much less important in the parasite. Another remarkable difference in the two metabolic pathways is that the glyoxalate cycle is operative in Leishmania spp. (33) and absent in the host. The glyoxalate cycle functions through an aldol cleavage of isocitrate to succinate and glyoxalate by the action of isocitrate liase (33) . Retardation of isocitrate formation caused by inhibition of aconitase by TAA may also affect the operation of the cycle, which plays a pivotal role in the replenishment of dicarboxylic acid intermediates of the tricarboxylic acid cycle from two-carbon substrates and synthesis of polysaccharide from acetate (33) . All of these reasons may cause the different adverse effects of TAA in the host and parasite.
In brief, it is found that the adverse effects of TAA are manifested primarily on the parasite, and no apparent signs and symptoms of toxicity in the animals were noted. However, to further demonstrate the efficacy and lack of toxicity of TAA, various studies must be done. These studies include the following: investigation of respiration of the parasite and host liver slices and determination of the P/O ratio; incorporation of radiolabelled glucose and acetate into metabolic intermediates of tricarboxylic acid and glyoxalate cycles and into cellular components of the host and parasite in the presence and absence of TAA; determination of K1, using TAA, for the enzyme aconitase of the host and parasite; and long-term toxicity of the drug in animals, etc.
